Institutional members access full text with Ovid®

FDA Review of Antismoking Aid, Varenicline, and Neuropsychiatric Adverse Events

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: February 2012 - Volume 112 - Issue 2 - p 28
doi: 10.1097/01.NAJ.0000411174.30943.cd
Drug Watch

* After reviewing two epidemiologic studies on the smoking cessation aid varenicline (Chantix), the Food and Drug Administration has concluded that the drug doesn't pose any greater risk of serious mood and behavior changes than the use of nicotine replacement therapy.

* Additional information about the safety risks of varenicline may be gleaned from a clinical trial sponsored by the drug manufacturer that will be completed in 2017.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2012 Lippincott Williams & Wilkins, Inc.